Atef M. Shibl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Atef M. Shibl has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Ziad Ahmed Memish
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
4 shared publications - Abiola Senok
College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates
3 shared publications M.S. Niederman
3 shared publicationsQ.A. Ahmed
3 shared publicationsZ. Memish
3 shared publicationsZiad Memish
3 shared publications
Latest Publications
- Open Access
- 1 April 2015
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 23 (2) , 107-114
Role of Probiotics in health improvement, infection control and disease treatment and management
Research which concerns the usefulness of Probiotics show increasing interest based on the rise of their publications, products and the awareness of the public of their benefits. There is increasing interest concerning Probiotics from the public, researchers, governmental organizations (such as the WHO/FAO) and medicinal and food companies. Probiotics means "let good microbes work for you in different fields get their benefits and take a rest". Such work will include, food digestion, production of useful products to destroy the bad microbes, complement the functions of the missed digestive enzymes (due to missed or defective genes), and to maintain the digestive system's pH, and so on. Probiotics will augment the efficiency of our biological fermentors, the digestive system. Many authors have described the history and the progress of Probiotics and their different applications. In this review, we will focus mainly on three points, health improvement, infection control and disease management, which could be eliminated by the use of different types of direct uses of Probiotics or by the use of foods containing Probiotics.
- 1 April 2015
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 23 (2) , 107-114
Open AccessRole of Probiotics in health improvement, infection control and disease treatment and management
Research which concerns the usefulness of Probiotics show increasing interest based on the rise of their publications, products and the awareness of the public of their benefits. There is increasing interest concerning Probiotics from the public, researchers, governmental organizations (such as the WHO/FAO) and medicinal and food companies. Probiotics means "let good microbes work for you in different fields get their benefits and take a rest". Such work will include, food digestion, production of useful products to destroy the bad microbes, complement the functions of the missed digestive enzymes (due to missed or defective genes), and to maintain the digestive system's pH, and so on. Probiotics will augment the efficiency of our biological fermentors, the digestive system. Many authors have described the history and the progress of Probiotics and their different applications. In this review, we will focus mainly on three points, health improvement, infection control and disease management, which could be eliminated by the use of different types of direct uses of Probiotics or by the use of foods containing Probiotics.
- Open Access
- 1 January 2014
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 13 (1) , 4
Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli in Riyadh: emergence of CTX-M-15-producing E. coli ST131
The prevalence of extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) has increased recently. The aim of this study was to further characterise and to assess the occurrence of ESBL-EC in Riyadh, to use pulsed field gel electrophoresis (PFGE) typing to investigate the epidemiology of ESBL-EC and to determine the prevalence of ST131 in ESBL-EC.
- 1 January 2014
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 13 (1) , 4
Open AccessMolecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli in Riyadh: emergence of CTX-M-15-producing E. coli ST131
The prevalence of extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) has increased recently. The aim of this study was to further characterise and to assess the occurrence of ESBL-EC in Riyadh, to use pulsed field gel electrophoresis (PFGE) typing to investigate the epidemiology of ESBL-EC and to determine the prevalence of ST131 in ESBL-EC.
- 6 December 2013
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 26 (1) , 13-18
National surveillance of antimicrobial resistance among Gram-positive bacteria in Saudi Arabia
Background: Antimicrobial-resistant Gram-positive bacteria are important causes of serious infections. Methods: Between January and December 2009, we examined clinical Gram-positive isolates from 24 hospitals across Saudi Arabia. Results: Among the 13750 isolates, Staphylococcus aureus (62.3%) was the commonest, followed by non-group A beta-haemolytic streptococci (14.8%), group A beta-haemolytic streptococci (7.1%), coagulase-negative staphylococci (6.6%), pneumococci (6.0%), and enterococci (3.1%). Resistance rates were high among S. aureus (methicillin-resistant S. aureus: 32%), coagulase-negative staphylococci (oxacillin: 63%) and pneumococci (penicillin G: 33%; erythromycin: 26%; ceftriaxone: 11%); low among enterococci (vancomycin: 1%) and among beta-haemolytic streptococci. Resistance rates varied between regions, but comparison was complicated by differences in antibiotics tested. Many relevant antibiotics were tested against few isolates (e. g. ampicillin, vancomycin, and high-level gentamicin versus enterococci) while unhelpful tests were widely performed (e. g. cefotaxime, ceftriaxone, and imipenem versus staphylococci. Conclusion: Resistance is widespread in staphylococci and pneumococci, but not enterococci and beta-haemolytic streptococci in Saudi Arabia. Rationalization of antibiotic panels tested is urgently needed.
- 6 December 2013
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 26 (1) , 13-18
National surveillance of antimicrobial resistance among Gram-positive bacteria in Saudi Arabia
Background: Antimicrobial-resistant Gram-positive bacteria are important causes of serious infections. Methods: Between January and December 2009, we examined clinical Gram-positive isolates from 24 hospitals across Saudi Arabia. Results: Among the 13750 isolates, Staphylococcus aureus (62.3%) was the commonest, followed by non-group A beta-haemolytic streptococci (14.8%), group A beta-haemolytic streptococci (7.1%), coagulase-negative staphylococci (6.6%), pneumococci (6.0%), and enterococci (3.1%). Resistance rates were high among S. aureus (methicillin-resistant S. aureus: 32%), coagulase-negative staphylococci (oxacillin: 63%) and pneumococci (penicillin G: 33%; erythromycin: 26%; ceftriaxone: 11%); low among enterococci (vancomycin: 1%) and among beta-haemolytic streptococci. Resistance rates varied between regions, but comparison was complicated by differences in antibiotics tested. Many relevant antibiotics were tested against few isolates (e. g. ampicillin, vancomycin, and high-level gentamicin versus enterococci) while unhelpful tests were widely performed (e. g. cefotaxime, ceftriaxone, and imipenem versus staphylococci. Conclusion: Resistance is widespread in staphylococci and pneumococci, but not enterococci and beta-haemolytic streptococci in Saudi Arabia. Rationalization of antibiotic panels tested is urgently needed.
- 1 December 2013
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 17 (12) , e1130-e1133
The emergence of OXA-48- and NDM-1-positive Klebsiella pneumoniae in Riyadh, Saudi Arabia
- 1 December 2013
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 17 (12) , e1130-e1133
The emergence of OXA-48- and NDM-1-positive Klebsiella pneumoniae in Riyadh, Saudi Arabia
- 1 April 2013
- Published by World Health Organization Regional Office for the Eastern Mediterranean (WHO/EMRO) in Eastern Mediterranean Health Journal
- Vol. 19 (04) , 389-392
Consensus recommendation for meningococcal disease prevention for Hajj and Umra pilgrimage/travel medicine
The Islamic Hajj to Makkah (Mecca) has been associated with outbreaks of invasive meningococcal disease and the global spread of Neisseria meningitidis serogroup W-135. For Hajj pilgrims the quadrivalent vaccination against serogroups A, C, W-135 and Y is a mandatory requirement. Novel conjugate vaccines may provide benefits for the community by reduction of carriage. With the introduction of the new generation of quadrivalent meningococcal conjugate vaccines (Menveo, Menactra, and others pending license) and their recent implementation in Saudi Arabia, experts from 11 countries in the Middle East region met at a Meningococcal Leadership Forum (MLF), in Dubai in May 2010 to exchange opinions on meningococcal disease and prevention strategies. These experts discussed the importance of introducing conjugate vaccines for pilgrims and travellers, and elaborated a consensus recommendation to support healthcare professionals and decision-makers.
- 1 April 2013
- Published by World Health Organization Regional Office for the Eastern Mediterranean (WHO/EMRO) in Eastern Mediterranean Health Journal
- Vol. 19 (04) , 389-392
Consensus recommendation for meningococcal disease prevention for Hajj and Umra pilgrimage/travel medicine
The Islamic Hajj to Makkah (Mecca) has been associated with outbreaks of invasive meningococcal disease and the global spread of Neisseria meningitidis serogroup W-135. For Hajj pilgrims the quadrivalent vaccination against serogroups A, C, W-135 and Y is a mandatory requirement. Novel conjugate vaccines may provide benefits for the community by reduction of carriage. With the introduction of the new generation of quadrivalent meningococcal conjugate vaccines (Menveo, Menactra, and others pending license) and their recent implementation in Saudi Arabia, experts from 11 countries in the Middle East region met at a Meningococcal Leadership Forum (MLF), in Dubai in May 2010 to exchange opinions on meningococcal disease and prevention strategies. These experts discussed the importance of introducing conjugate vaccines for pilgrims and travellers, and elaborated a consensus recommendation to support healthcare professionals and decision-makers.
- Open Access
- 1 November 2012
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 18 (11) , 1068-1080
Infectious diseases in the Arabian Peninsula and Egypt
- 1 November 2012
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 18 (11) , 1068-1080
Open AccessInfectious diseases in the Arabian Peninsula and Egypt
- Open Access
- 1 January 2012
- Published by Springer Nature in Journal of Epidemiology and Global Health
- Vol. 2 (1) , 23-30
Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region
Facing the availability of the new generation of quadrivalent meningococcal conjugate vaccines (Menveo®, Menactra® and others pending for license) and their recent implementation in Saudi Arabia, experts from 11 countries of the Middle East region met at a "Meningococcal Leadership Forum" (MLF), which took place in May 2010 in Dubai. The participants of the conference discussed the importance of introducing the concept of conjugate vaccines - especially for children and adolescents - and elaborated a consensus recommendation to support healthcare professionals and decision makers with their expertise. In experts' opinion, conjugate vaccines are the best choice for the prevention of meningococcal disease caused by serogroups A, C, W-135 and Y. As quadrivalent meningococcal conjugate vaccines are registered and available in the Middle East region, they should replace plain polysaccharide vaccines and be integrated in pediatric and adolescent vaccination schedules, including infant vaccination concomitantly with basic EPI vaccines when licensed.
- 1 January 2012
- Published by Springer Nature in Journal of Epidemiology and Global Health
- Vol. 2 (1) , 23-30
Open AccessConsensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region
Facing the availability of the new generation of quadrivalent meningococcal conjugate vaccines (Menveo®, Menactra® and others pending for license) and their recent implementation in Saudi Arabia, experts from 11 countries of the Middle East region met at a "Meningococcal Leadership Forum" (MLF), which took place in May 2010 in Dubai. The participants of the conference discussed the importance of introducing the concept of conjugate vaccines - especially for children and adolescents - and elaborated a consensus recommendation to support healthcare professionals and decision makers with their expertise. In experts' opinion, conjugate vaccines are the best choice for the prevention of meningococcal disease caused by serogroups A, C, W-135 and Y. As quadrivalent meningococcal conjugate vaccines are registered and available in the Middle East region, they should replace plain polysaccharide vaccines and be integrated in pediatric and adolescent vaccination schedules, including infant vaccination concomitantly with basic EPI vaccines when licensed.
- 31 May 2009
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 33 (5) , 410.e1-410.e9
Epidemiology of invasive pneumococcal disease in the Arabian Peninsula and Egypt
- 31 May 2009
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 33 (5) , 410.e1-410.e9
Epidemiology of invasive pneumococcal disease in the Arabian Peninsula and Egypt
- Open Access
- 1 September 2008
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 14 (9) , 876-879
Distribution of serotypes and antibiotic resistance of invasive pneumococcal disease isolates among children aged 5 years and under in Saudi Arabia (2000–2004)
- 1 September 2008
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 14 (9) , 876-879
Open AccessDistribution of serotypes and antibiotic resistance of invasive pneumococcal disease isolates among children aged 5 years and under in Saudi Arabia (2000–2004)